

February 9, 2026

Company name	CellSource Co., Ltd.
Name of representative	Masayuki Yamakawa, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information	Tomohiro Iga, Director and CFO
	Tel: +81-3-6455-5308

## January 2026 Monthly KPI Fiscal Year Ending October 2026


We are pleased to announce the KPI results for our contract processing services for January 2026, under the fiscal year ending October 2026. Please note that these figures are preliminary and may be subject to revision in quarterly reports or other disclosures.

### 1. Daily Average Number of Contract Processing Orders




- The daily average number of contract processing orders for January increased year-on-year to 54.3 orders.
- By department, the number of contract processing orders for blood-derived products from self-funded orthopedics decreased by 43 orders year-on-year, while there was a 79-order increase from hybrid orthopedics, and an 11-order increase from OB&GYN, and 4-order decrease in contract processing orders for aesthetic medicine.

## 2. Monthly Contract Processing Orders for Blood-derived Products by Department



- In January 2026, the number of contract processing orders for blood-derived products by department was as follows: 705 orders for self-funded orthopedics, representing a 5.7% decrease year-on-year, and 761 orders for hybrid orthopedics, an increase of 11.6% year-on-year.
- For self-funded orthopedics, we have continued to strengthen the organizational structure of the medical corporation through business support services enhanced in last fiscal year, although the number of orders has recently decreased.
- For hybrid orthopedics, the number of contract processing orders increased year-on-year due to the implementation of measures targeting key medical institutions.
- Orders for OB&GYN increased by 11 orders (up 12.4% year-on-year), and aesthetic medicine decreased by 4 orders (down 26.7% year-on-year).

### 3. Change in Blood-Derived Product Processing Orders from Hybrid Clinics



- "Group 1" represents the core client base that forms the foundation of the company's sales, where the company aims for a stable increase in order volume by continuously allocating a certain number of sales resources. On the other hand, "Group 2" primarily consists of other medical institutions and newly partnered medical institutions, and is positioned as a group aiming to expand order volume by supporting the launch of new partner clinics and promoting service utilization.
- The total order volume for the period slightly increased year-on-year to 1,990 orders. Excluding "free-of-charge products," the volume increased by 7.6% year-on-year.
- Regarding Group 1, order volume decreased by 99 orders year-on-year (down 0.3 orders per clinic) due to the continued impact of some orders being moved forward following specific measures implemented in October; however, a recovery trend is emerging, with an increase of 15 orders compared to the previous month driven by ongoing follow-up and proposal activities for existing priority medical institutions.
- Regarding Group 2, the strategy of refreshing KPIs from the current fiscal year has begun to yield positive results, leading to a year-on-year increase of 245 orders (up 0.2 orders per clinic).

**CellSource Co., Ltd.**

CellSource specializes in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3240004) in accordance with the Act on the Safety of Regenerative Medicine, it has handled over 120,000 cell-related procedures. With a wealth of experience, it strives to offer reliable services to medical institutions and contribute to research and technological development.

Homepage: <https://www.cellsource.co.jp/en/>  
IR Library : <https://www.cellsource.co.jp/en/ir/documents/>  
Official note : <https://note.cellsource.co.jp/> (in Japanese)  
IR Inquiries : [https://www.cellsource.co.jp/contact/index\\_ir.html](https://www.cellsource.co.jp/contact/index_ir.html)

*Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete.*

*In the event of any translation error or misunderstanding, the original Japanese version shall prevail.*